Clinical trial NCT02195934: The Orange Juice and Cardiovascular Disease Study
Official title: The Orange Juice and Cardiovascular Disease Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Disease
Keywords: Cardiovascular disease, blood orange juice, anthocyanins
Lead sponsor: Quadram Institute Bioscience
Sponsor class: OTHER
Collaborators: name: European Commission
name: Biotechnology and Biological Sciences Research Council
First posted: 2014-07-21
Enrollment: 41
Sex: ALL
Minimum age (years): 25
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to compare the effect of an anthocyanin-rich blood orange juice with a standard (no anthocyanin) blonde orange juice on markers of cardiovascular disease (CVD).

Participants aged between 25 and 84 years of age will be recruited into a single arm, two way cross-over study based on their waist measurement, with 42 individuals required to complete the study. Participants will each receive two interventions in a randomised order: 500mL blood orange juice daily for 28 days, and 500ml standard (blonde) orange juice daily for 28 days.

Prior to each intervention there will be a 2 week "run in period" where participants will be asked to avoid consuming foods rich in anthocyanins. After the first 28 day intervention period, there will be a 3 week wash out period after which the participants will be asked to then drink the other juice for 28 days. The 500 mL of blood orange juice contains approximately 50mg of anthocyanins, whereas the standard juice contains none.

Blood samples will be collected for the preparation of plasma and peripheral blood mononuclear cells (PBMCs) for the analysis of anthocyanin metabolite concentrations, transcriptomics and CVD risk markers. Urine samples will be collected and urinary excretion of anthocyanin metabolites will be quantified. Other measurements will include pulse wave analysis, pulse wave velocity, central blood pressure, waist and hip circumference, blood glucose, glycated haemoglobin (HbA1C) and insulin concentrations, and various measurements using the TANITA machine which include weight, fat mass, muscle mass, fat percentage, fat-free mass, total body water, bone mass, metabolic age, basal metabolic rate, visceral fat rating, and degree of obesity. All measurements and samples will be taken at baseline and post intervention for each phase of the study.


Eligibility criteria: Inclusion Criteria:

* Men and women aged 25-84 years
* Waist measurement

  * Caucasians: Men \> 102cm (40inches); Women \>88cm (34inches)
  * Asians: Men\> 90cm (35inches); Women 80cm (31inches)

Exclusion Criteria:

* Those unable to give written informed consent
* Those unwilling to provide general practitioner (GP) details
* Regular prescribed medication that may affect study outcome. This will be assessed on an individual basis-not including statins
* Over-the-counter (non-prescribed) medication that may affect the study data. This will be assessed on an individual basis.
* Allergy to the test juice drink or the actual fruit itself
* Chronic medical conditions requiring active treatment. This will be assessed on an individual basis
* Those already consuming blood orange juice, unless they are willing to discontinue consumption for 2 weeks prior to starting the study.
* Diagnosed diabetics;
* Peri-menopausal women (defined as: when there is a permanent change in menstrual cycle)
* Women on hormone replacement therapy (HRT) for less than one year
* On thyroxine for less than one year
* Women who are pregnant, have been pregnant within the last 12 months or who are breastfeeding
* Those taking aspirin (prescribed or self-prescribed)
* All blood pressure medication
* Those individuals who happen to be on statins will be excluded if they have been on statins for less than 3 months; or if they are not taking on a daily basis; or those who have recently changed their dosage of statins. This will be assessed on an individual basis
* Those on regular medication for hypercoagulation and inflammatory conditions e.g. corticosteroids and asthma. The intermittent use of an inhaler will be discussed on an individual basis
* Those who have had a cardiovascular event such as stroke, myocardial infarction (heart attack) or trans ischemic attacks in the past and deemed unsuitable for participation in the study. This will be discussed with the medical adviser on an individual basis
* Peripheral vascular disease including claudication
* Consumption of fish oil supplements (unless participant is willing to discontinue their use 8 weeks prior to the start of the intervention- all other supplements will be assessed on an individual basis
* Parallel participation in another research project which has involved dietary intervention and/or sampling of blood
* Any person related to or living with any member of the study team
* Participation in another research project which involves blood sampling within the last four months unless the total blood from both studies (including this one) does not exceed 470mL)
* Those who have donated or intend to donate blood within 16 weeks of the first and last study samples
* Gastrointestinal disease (excluding hiatus hernia) unless symptomatic or study intervention/procedure is contraindicated
* Those undergoing any on-going clinical investigations with their GP or hospital clinic.
* Those who have had throat surgery or neck injury
* Those with internal medical devices

Screening exclusion criteria

* Results of the eligibility screening that indicate or are judged by the Institute of Food Research Human Nutrition Unit (HNU) medical adviser to be indicative of a health problem which could compromise the well-being of the participant if they participated or could affect the study data.
* BMI \<19.5
* Weight \>180kg (28stones)
* Fasting total cholesterol \> 8.0mmol/L
* Haemoglobin Men \<13.8g/dL (8.56mmol/L) Women \<12.1g/dL (\<5.51mmol/L)
* Fasting glucose \>6mmol/L
* Blood pressure \<90/50mmHg or 95/55mmHg if symptomatic; \>160/100mmHg
* Anyone with any internal medical devices (incompatible with the TANITA)

Primary outcomes:
measure: LDL cholesterol
timeFrame: 28 days (4 weeks)
Secondary outcomes:
measure: CVD biomarkers
timeFrame: 28 days (4 weeks)
Other outcomes:
measure: Gene expression
timeFrame: 28 days (4 weeks)
Locations:
city: Norwich
country: United Kingdom
facility: Institute of Food Research
state: Norfolk
Study officials:
affiliation: Quadram Institute Bioscience
name: Paul A Kroon, PhD
role: STUDY_DIRECTOR
affiliation: Quadram Institute Bioscience
name: Charlotte N Armah, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Quadram Institute Bioscience
name: Joanne F Doleman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hollands WJ, Armah CN, Doleman JF, Perez-Moral N, Winterbone MS, Kroon PA. 4-Week consumption of anthocyanin-rich blood orange juice does not affect LDL-cholesterol or other biomarkers of CVD risk and glycaemia compared with standard orange juice: a randomised controlled trial. Br J Nutr. 2018 Feb;119(4):415-421. doi: 10.1017/S0007114517003865.